NCT05231122 2026-03-16
Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for the Treatment of Patients With Recurrent Ovarian Cancer
Roswell Park Cancer Institute
Phase 2 Recruiting
Clinical Trials
17 trialsNCT06366347 2026-02-11
ALPINE: Maintenance Letrozole/Abemaciclib
Dana-Farber Cancer Institute
Phase 2 Recruiting
NCT00977574 2025-10-31
Paclitaxel, Carboplatin, and Bevacizumab or Paclitaxel, Carboplatin, and Temsirolimus or Ixabepilone, Carboplatin, and Bevacizumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT03587311 2025-10-08
Bevacizumab and Anetumab Ravtansine or Paclitaxel in Treating Patients With Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT03026062 2025-09-19
Durvalumab and Tremelimumab in Treating Participants With Recurrent or Refractory Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
M.D. Anderson Cancer Center
Phase 2 Completed
NCT04919629 2025-05-11
APL-2 and Pembrolizumab Versus APL-2, Pembrolizumab and Bevacizumab Versus Bevacizumab Alone for the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer and Malignant Effusion
Roswell Park Cancer Institute
Phase 2 Recruiting
NCT02312245 2024-12-05
Avatar-Directed Chemotherapy in Treating Patients With Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Mayo Clinic
Phase 2 Completed
NCT02953457 2024-11-19
Olaparib, Durvalumab, and Tremelimumab in Treating Patients With Recurrent or Refractory Ovarian, Fallopian Tube or Primary Peritoneal Cancer With BRCA1 or BRCA2 Mutation
Roswell Park Cancer Institute
Phase 2 Completed
NCT02923739 2024-03-13
Paclitaxel and Bevacizumab With or Without Emactuzumab in Treating Patients With Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT02921269 2023-02-21
Atezolizumab and Bevacizumab in Treating Patients With Recurrent, Persistent, or Metastatic Cervical Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT01097746 2022-10-28
First-Line Treatment of Bevacizumab, Carboplatin, and Paclitaxel in Treating Participants With Stage III-IV Ovarian, Primary Peritoneal, and Fallopian Tube Cancer
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00886691 2022-02-04
Bevacizumab With or Without Everolimus in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
GOG Foundation
Phase 2 Completed
NCT02853318 2021-10-06
Pembrolizumab, Bevacizumab, and Cyclophosphamide in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Roswell Park Cancer Institute
Phase 2 Completed
NCT00748657 2019-07-23
Bevacizumab in Treating Patients With Recurrent Sex Cord-Stromal Tumors of the Ovary
National Cancer Institute (NCI)
Phase 2 Completed
NCT01010126 2019-01-25
Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00369122 2018-03-20
Bevacizumab, Radiation Therapy, and Cisplatin in Treating Patients With Previously Untreated Locally Advanced Cervical Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00072566 2015-05-12
Bevacizumab and Low-Dose Cyclophosphamide in Treating Patients With Recurrent Ovarian Epithelial or Primary Peritoneal Cancer
National Cancer Institute (NCI)
Phase 2 Completed